Search
CM4620
go.drugbank.com/drugs/DB16466InvestigationalCM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066
INO-4800
go.drugbank.com/drugs/DB15693Investigational[A214475] Early _in vitro_ studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells. … Furthermore, the antibodies produced were capable of inhibiting the binding of SARS-CoV-2 to the ACE2 receptor, which is thought to be critical for host cell entry.
RP01
go.drugbank.com/drugs/DB05751ExperimentalIt is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. … It could offer benefit to millions of asthma and allergy patients.
Flumethasone
go.drugbank.com/drugs/DB00663ApprovedVet approvedFlumethasone is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of applicati...
Ranirestat
go.drugbank.com/drugs/DB05327InvestigationalIt has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy.
IR208
go.drugbank.com/drugs/DB05106InvestigationalIR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. … It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.
Padimate A
go.drugbank.com/drugs/DB11229ApprovedWithdrawnIt absorbs ultraviolet rays thereby preventing sunburn, however, its chemical structure and behaviour is similar to an industrial free radical generator.
Olcegepant
go.drugbank.com/drugs/DB04869InvestigationalOlcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.
Tetrahydrocannabivarin
go.drugbank.com/drugs/DB11755InvestigationalAlthough THCV possesses an almost identical structure to Δ9-THC (varying only by the length of its lipophilic alkyl chain), it has different molecular targets and pharmacological profile [A32972]. … Beyond the endocannabinoid system, THCV has also been reported to activate 5HT1A receptors to produce an antipsychotic effect that has therapeutic potential for ameliorating some of the negative, cognitive
Festuca pratensis pollen
go.drugbank.com/drugs/DB10370ApprovedFestuca pratensis pollen is the pollen of the Festuca pratensis plant. Festuca pratensis pollen is mainly used in allergenic testing.
Mixtures: Mixture of Twenty-Two Standardized and Non-Standardized Grasses